Revlimid 5 mg Capsules Special Use-results Surveillance (All-case Surveillance)

Trial Profile

Revlimid 5 mg Capsules Special Use-results Surveillance (All-case Surveillance)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Multiple myeloma; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 26 May 2017 Planned End Date changed from 1 Jun 2020 to 19 Jun 2020.
    • 05 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top